

Erratum

Vol. 71, No. 3

In the report “Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 — United States, March 2020–August 2021,” on p. 98, in Table 1, under the “Inpatients with positive SARS-CoV-2 test result” column, the numbers and percentages for the following rows listed under “Medical conditions associated with high risk” should have read Anemia “**28,645 (23.8)**,” Arrhythmia “**33,443 (27.8)**,” Asthma “**14,542 (12.1)**,” COPD “**13,447 (11.2)**,” Cancer “**11,642 (9.7)**,” Chronic kidney disease “**26,221 (21.8)**,” Chronic pulmonary disorders “**28,994 (24.1)**,” Coagulopathy “**18,908 (15.7)**,” Congestive heart failure “**21,246 (17.7)**,” Coronary artery disease “**25,308 (21.1)**,” Diabetes type 2 “**41,888 (34.8)**,” Hypertension “**69,671 (58.0)**,” Mental health disorders “**23,857 (19.8)**,” Peripheral vascular disorders “**14,484 (12.0)**,” and Severe obesity (BMI ≥ 40 kg/m²) “**17,716 (14.7)**.”

On p. 99, in Table 2, under the column heading, “Total no. eligible for treatment,” the numbers for the row headings “Monoclonal antibodies (November 2020–August 2021): Ethnicity,” should have read Non-Hispanic “**387,403**,” and Hispanic “**80,176**,” and the percentages in the same rows under the column “Total no. (%) treated” should have read Non-Hispanic “**(2.9)**,” and Hispanic “**(1.3)**.” These corrections do not affect findings of this report.